I-Mab’s Promising Q3 Results and Strategic Moves
I-Mab, a U.S.-based biotech firm, reported promising financial and clinical advancements in its third-quarter 2024 results. The company is set to initiate a Phase 2 study for uliledlimab in lung ...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...
Le Lézard15h
Zoomcar Reports Significant Profitability Improvement in its Second Quarter Financial 2024 Results
Zoomcar Holdings, Inc.  ('Zoomcar,' or 'we,' or 'our'), the leading marketplace for car sharing in India, today announced results for its second quarter ended September 30, 2024. Hiroshi Nishijima, ...